中国肺癌杂志
中國肺癌雜誌
중국폐암잡지
CHINESE JOURNAL OF LUNG CANCER
2015年
1期
42-47
,共6页
肺肿瘤%腺癌%鳞癌%癌基因%靶向治疗
肺腫瘤%腺癌%鱗癌%癌基因%靶嚮治療
폐종류%선암%린암%암기인%파향치료
Lung neoplasms%Adenocarcinoma%Squamous cell carcinoma%Oncogenes%Targeted therapy
腺癌和鳞癌是非小细胞肺癌（non-smallcelllungcancer,NSCLC）最常见的两种病理类型。一些诱发和维持恶性肿瘤的分子改变被称为驱动基因。随着多重基因分型和高通量基因组分析等下一代（next-generationsequencing,NGS）测序技术的推广运用，使得从微小的肿瘤活检标本中检测病患者的癌症基因组成为可能，基于基因特征的临床研究也相继开展，进一步推动对NSCLC的分子分型。肺腺癌中约60%的驱动基因被确定，肺鳞癌驱动基因的检出率也在逐步提高，其中表皮生长因子受体（epidermalgrowthfactorreceptor,EGFR）、间变性淋巴瘤激酶（anaplasticlymphomakinase,ALK）、成纤维细胞生长因子受体1（fibroblastgrowthfactorreceptor1,FGFR1）、磷脂酰肌醇3激酶催化亚单位A（phosphatidylinositol3-kinasecatalyticsubunitalpha,PIK3CA）等起着重要作用，目前临床上有效的驱动基因靶向治疗主要是针对EGFR、ALK等。本文将对NSCLC驱动基因的意义及相关研究进行综述。
腺癌和鱗癌是非小細胞肺癌（non-smallcelllungcancer,NSCLC）最常見的兩種病理類型。一些誘髮和維持噁性腫瘤的分子改變被稱為驅動基因。隨著多重基因分型和高通量基因組分析等下一代（next-generationsequencing,NGS）測序技術的推廣運用，使得從微小的腫瘤活檢標本中檢測病患者的癌癥基因組成為可能，基于基因特徵的臨床研究也相繼開展，進一步推動對NSCLC的分子分型。肺腺癌中約60%的驅動基因被確定，肺鱗癌驅動基因的檢齣率也在逐步提高，其中錶皮生長因子受體（epidermalgrowthfactorreceptor,EGFR）、間變性淋巴瘤激酶（anaplasticlymphomakinase,ALK）、成纖維細胞生長因子受體1（fibroblastgrowthfactorreceptor1,FGFR1）、燐脂酰肌醇3激酶催化亞單位A（phosphatidylinositol3-kinasecatalyticsubunitalpha,PIK3CA）等起著重要作用，目前臨床上有效的驅動基因靶嚮治療主要是針對EGFR、ALK等。本文將對NSCLC驅動基因的意義及相關研究進行綜述。
선암화린암시비소세포폐암（non-smallcelllungcancer,NSCLC）최상견적량충병리류형。일사유발화유지악성종류적분자개변피칭위구동기인。수착다중기인분형화고통량기인조분석등하일대（next-generationsequencing,NGS）측서기술적추엄운용，사득종미소적종류활검표본중검측병환자적암증기인조성위가능，기우기인특정적림상연구야상계개전，진일보추동대NSCLC적분자분형。폐선암중약60%적구동기인피학정，폐린암구동기인적검출솔야재축보제고，기중표피생장인자수체（epidermalgrowthfactorreceptor,EGFR）、간변성림파류격매（anaplasticlymphomakinase,ALK）、성섬유세포생장인자수체1（fibroblastgrowthfactorreceptor1,FGFR1）、린지선기순3격매최화아단위A（phosphatidylinositol3-kinasecatalyticsubunitalpha,PIK3CA）등기착중요작용，목전림상상유효적구동기인파향치료주요시침대EGFR、ALK등。본문장대NSCLC구동기인적의의급상관연구진행종술。
Adenocarcinoma and squamous cell carcinoma are the most common histological types of non-small cell lung cancer (NSCLC). Several molecular alterations have been defined as "driver oncogenes" responsible for both the initia-tion and maintenance of the malignancy. With next-generation sequencing (NGS) which having multiple and high-throughput genotyping is wildly used and promoted, make the detection of patients gene composition from a tiny tumor biopsy specimens become possible, initiate the clinical studies based on the genetic characteristics, and promote the progress of molecular typing in NSCLC. So far, about 60% of lung adenocarcinoma has been found harbouring driver oncogenes, the rate of lung squamous cell carcinoma driven genes detection has gradually improved, in which epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), fibroblast growth factor receptor 1 (FGFR1), phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) and so on plays important roles. Te currently efective targeted therapies is mainly used against EGFR, ALK, etc. In this review, we will report the mainly advances on some latest driver mutations of NSCLC.
